JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Portier, M.
Right arrow Articles by Casellas, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Portier, M.
Right arrow Articles by Casellas, P.

Vol. 288, Issue 2, 582-589, February 1999

SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist

Marielle Portier, Murielle Rinaldi-Carmona, Florence Pecceu, Thérèse Combes, Caroline Poinot-Chazel, Bernard Calandra, Francis Barth, Gérard Le Fur and Pierre Casellas

Sanofi Recherche, Montpellier Cedex, France (M.P., M.R.-C., T.C., C.P.-C., F.B., P.C.); Sanofi Recherche, Labège Cedex, France (F.P., B.C.); and Sanofi Recherche, Paris, France (G. Le F.)

In the present report, we investigated in detail the effects of SR 144528, a selective antagonist of the peripheral cannabinoid receptor (CB2), on two well-characterized functions mediated by CB2: the induction of the early response gene krox24 and the inhibition of adenylyl cyclase. We generated Chinese hamster ovary cells doubly transfected with human CB2 and a luciferase reporter gene linked to either the murine krox24 regulatory sequence or multiple cAMP responsive elements. Our results show that (1) SR 144528 antagonizes the effect of receptor agonists---it inhibits the krox24 reporter activity and prevents the inhibition of forskolin-induced cAMP reporter activity mediated by CP 55,940; (2) CB2 is autoactivated---CB2 mediates signaling in the absence of ligand, and this basal activity is reduced by pretreating the cells with pertussis toxin; (3) SR 144528 is an inverse agonist---it reproduces the effects of pertussis toxin; and (4) inhibition of precoupled CB2 by a long-term pretreatment of cells with SR 144528 potentiates krox24 response to cannabinoid receptor agonists and restores activation of adenylyl cyclase. Taken together, these data provide evidences for the inverse agonist property of SR 144528 and the constitutive activation of CB2 in Chinese hamster ovary-expressing cells.

0022-3565/99/2882-0582$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
A. E. B. Springs, P. W. F. Karmaus, R. B. Crawford, B. L. F. Kaplan, and N. E. Kaminski
Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by {Delta}9-tetrahydrocannabinol
J. Leukoc. Biol., December 1, 2008; 84(6): 1574 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Q. Zhang, P. Ma, W. Wang, R. B. Cole, and G. Wang
IN VITRO METABOLISM OF DIARYLPYRAZOLES, A NOVEL GROUP OF CANNABINOID RECEPTOR LIGANDS
Drug Metab. Dispos., April 1, 2005; 33(4): 508 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Kenakin
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Plant Physiol.Home page
S. Tripathy, K. Kleppinger-Sparace, R. A. Dixon, and K. D. Chapman
N-Acylethanolamine Signaling in Tobacco Is Mediated by a Membrane-Associated, High-Affinity Binding Protein
Plant Physiology, April 1, 2003; 131(4): 1781 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. J. McKallip, C. Lombard, M. Fisher, B. R. Martin, S. Ryu, S. Grant, P. S. Nagarkatti, and M. Nagarkatti
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
Blood, June 28, 2002; 100(2): 627 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al.
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Iwamura, H. Suzuki, Y. Ueda, T. Kaya, and T. Inaba
In Vitro and in Vivo Pharmacological Characterization of JTE-907, a Novel Selective Ligand for Cannabinoid CB2 Receptor
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 420 - 425.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J.-M. Derocq, O. Jbilo, M. Bouaboula, M. Segui, C. Clere, and P. Casellas
Genomic and Functional Changes Induced by the Activation of the Peripheral Cannabinoid Receptor CB2 in the Promyelocytic Cells HL-60. POSSIBLE INVOLVEMENT OF THE CB2 RECEPTOR IN CELL DIFFERENTIATION
J. Biol. Chem., May 19, 2000; 275(21): 15621 - 15628.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.